Darshana Zaveri

Darshana Zaveri is a Managing Partner of Catalyst Health Ventures. Darshana is actively involved in all aspects of Fund Management including Investments and Capital Raising. She led Catalyst’s investments in Augmenix (acquired by Boston Scientific, NYSE: BSX), Lantos Technologies, nVision Medical (acquired by Boston Scientific, NYSE: BSX), Maxwell Health (Acquired by Sun Life Financial, NYSE: SLF), Aria CV, and Hepregen. She currently represents Catalyst on the Boards of Lantos (past Chair), Aria CV (Chair), while previously serving on the boards of nVision, Augmenix, and Maxwell Health. She was also actively involved with portfolio company Allegro Diagnostics, Inc. (acquired by Veracyte, NASDAQ: VCT)

Darshana brings to Catalyst over a decade of experience in the health care and Life Science Industries. Prior to Catalyst, she was an Investigator at Vertex Pharmaceuticals and an integral part of the drug development programs in oncology, metabolic disease, and immunology. Previously she worked at Genome Therapeutics, a Massachusetts-based biotechnology company, at the Dana Farber Cancer Institute, and completed an internship at the United Nations. She has authored several publications and scientific journal articles and currently serves as a Catalyst of the Deshpande Center for Technological Innovation at MIT.

Darshana received an MPA from Harvard University, a MS degree in Cell and Molecular Biology from Boston University, and a BS in Biochemistry from Bombay University in Bombay, India.